BHI Team Members

Douglas Liu is a distinguished business leader and operations executive with over 40 years of comprehensive experience in the biotechnology industry, specializing in manufacturing, quality assurance, regulatory affairs, and global operations management. His career spans the complete biotechnology value chain from early-stage development through commercial manufacturing, with particular expertise in molecular diagnostics, clinical research, and international business development.

Dr. Albine Martin is a seasoned C-level executive with over three decades of experience translating innovation from laboratory to clinic. She currently serves as an Executive in Residence, where she focuses on triaging innovations and intellectual property portfolios toward company formation strategies while supporting the regional startup ecosystem. Dr. Martin earned her Ph.D. in Biochemistry from the University of Maryland, College Park, with a thesis on the biochemistry of lipid-linked pathways in oligosaccharide-linked protein pathways. She also holds a B.S. from Trinity College, Washington, DC, and has completed executive education programs at Cornell University (Certificate in Financial Management) and Harvard Business School (Leadership & Strategy Program in Pharmaceutical and Biotechnology).

Dr. Kimberly E. Martin is a distinguished scientific and clinical affairs executive with over 25 years of comprehensive experience bringing drugs and medical devices to market. As an Entrepreneur-in-Residence (EIR) and advisor to the National Institutes of Health (NIH), she combines deep technical expertise in clinical trial design and regulatory strategy with innovative leadership in pharmaceutical and medical device development across multiple therapeutic areas.

Kelly earned her master's in biotechnology from the McCormick School of Engineering at Northwestern University, building on her bachelor's degree in neuroscience and analytical-organic chemistry from the University of Nevada, Reno. With over 2 years at BioHealth Innovation and 15 grant writing projects under her belt, Kelly has developed expertise in translating complex scientific concepts and commercialization strategies into successful grant proposals. Kelly's diverse background in biotechnology, neuroscience, and chemistry enables her to support a wide range of clients in the life sciences sector, helping them secure funding for innovative research and development initiatives.

Jon earned his doctorate in biology from Wake Forest University, specializing in neuroscience and the molecular mechanisms that underlie behavior. His early academic journey, which includes bachelor's and master's degrees in biology, focused on epigenetics and oncology. Jon’s experience spans academia and industry, including work as a patent engineer where he contributed to several patent applications. Jon has been a member of BioHealth Innovation since 2023, and now serves as Manager of Client Engagement, leading the Analyst team, assisting with commercialization and pitch coaching, as well as spearheading grant writing projects. With over 7 years of grant writing experience, Jon leverages his diverse background to guide clients through the process of obtaining non-dilutive funding and commercialization.

Dr. Kuldeep Neote is a seasoned biotechnology executive and venture capital professional with over 25 years of experience in external innovation, business development, and strategic partnerships across the life sciences industry. His career encompasses roles at leading pharmaceutical companies, innovative biotech ventures, and investment organizations, with particular expertise in immunology, oncology, and gene therapy development.

John P. Reinhart is an accomplished C-suite executive and serial entrepreneur who specializes in Longevity Economy innovation, with nearly two decades of recognition for transformative contributions to healthcare and aging services. As a visionary leader in the intersection of technology, healthcare, and demographic change, he has co-founded multiple ventures and led organizations that address the evolving needs of America's aging population while creating scalable business solutions.

Dr. Loleta Robinson is the President & CEO of Fortis Industries, LLC and a physician entrepreneur and healthcare investment strategist. She is known for her ability to bridge clinical insight with business acumen—advancing innovation, guiding commercialization strategies, and aligning cutting-edge medical solutions with market needs. Throughout her career, Dr. Robinson has held pivotal roles at Thermo Electron Corporation and MedImmune Vaccines, and has served as an Entrepreneur in Residence at Blue Cross Blue Shield of Nebraska and the NIH SEED program. As a trusted advisor to startups, she offers strategic guidance on product development, payer engagement, and market access, with a steadfast commitment to clinical relevance, patient safety, and ethical rigor. She holds an MD from the University of Kansas School of Medicine, an MBA in Health Administration from the University of Colorado–Denver, and a Certificate in Venture Capital Finance from UC Berkeley School of Law. Dr. Robinson’s interdisciplinary expertise positions her at the forefront of healthcare innovation, driving growth and impact in a rapidly evolving landscape.

Dr. Ethel Rubin is a biotech strategy and finance executive with over 20 years of experience at the intersection of healthcare investment and commercialization. With a proven track record in leading high-impact business and corporate development activities, driving product and portfolio strategies, and engaging with investors and industry partners, she currently leads a team of venture professionals helping NIH portfolio companies navigate rapid growth cycles, prepare for capital raise, progress to valuation inflection points and exit.  In addition, she is an active business consultant to biotech, partnering with strong scientific and clinical teams to bridge the gap between breakthrough research and institutional-grade commercial strategy, building the financial architecture and strategic roadmap necessary to attract institutional investment or scale to an exit. In previous roles as an EIR for the NHLBI, she deployed a $40M pre-seed fund, resulting in over $1B in exits. From 2009-2015 she led global clinical strategy, external innovation and medical affairs at Medtronic, plc, with a focus on interventional technologies including the fast growing Afib ablation business. Prior to that, she was CSO/COO of two successful early stage companies: BioFortis, Inc. (acquired by IQVIA) and CSA Medical, Inc. Over the course of her career, Dr. Rubin took part in over 25 commercial product launches, was instrumental in multiple M&As, partnerships & collaborations, and capital raises totaling more than $2B. Ethel currently sits on the Board of a multinational biotech company, Volition Rx (NYSE:VNRX), a world leader in nucleosome detection and quantitiation, and was previously a Director at Innara Health, Inc., where she helped attract strategic investment and exit in 3 years via acquisition by Cardinal Health (NYSE:CAH). She is an advisor or mentor to numerous companies through both private engagement as well as NYU Stern School of Business’ Endless Frontier Labs. Dr. Rubin earned a PhD in Biochemistry and Biophysics from the University of Rochester School of Medicine & Dentistry and was a research fellow at Johns Hopkins University School of Medicine, where she led independent breast cancer research that identified developmental gene re-expression in adult tumors. She earned a certificate in Corporate Governance from The George Washington University School of Business and is an LP in VC funds focused on women’s health as well as an advisor to First Bight Ventures. Ethel maintains media presence as a sought-after speaker, moderator or pitch judge. Check out her articles on www.linkedin.com/in/ethelrubinphd/.

Mona earned her doctorate in Biochemistry from Virginia Commonwealth University and her MBA from George Mason University. With over eight years of experience as a consultant in the business and science sectors, Mona brings a unique blend of scientific expertise and business acumen to her role at BioHealth Innovation. She specializes in entrepreneurship, innovation, strategy, and marketing, assisting companies in developing comprehensive marketing strategies, product launch plans, and development strategies. Mona diverse background enables her to help clients transform their scientific innovations into marketable products and services in the competitive life sciences landscape.

John Sullivan is a proven leader in healthcare innovation with extensive experience building, operating, and acquiring market-leading businesses that leverage technology to improve health outcomes, drive operational efficiencies, and reduce healthcare costs. Throughout his career, he has demonstrated exceptional ability to work closely with customers, understand complex market needs, and develop products and services designed for rapid marketplace adoption. His comprehensive background spans multiple healthcare sectors including medical devices, biotechnology, healthcare IT, digital health, consumer health, pharmacy, and supply chain management.

Kwame Ulmer is a distinguished medical technology executive and regulatory strategist with over 20 years of experience navigating the complex intersection of innovation, regulation, and commercialization in healthcare. As Managing Partner of MedTech Impact Partners, a specialized regulatory strategy consulting firm, Kwame has established himself as a trusted advisor to medical device companies seeking to successfully navigate FDA requirements and bring life-changing technologies to market.